ESBATech is a drug discovery and development company focusing on therapeutic applications of its proprietary antibody fragments derived from fully human antibody fragment scaffolds. ESBATech’s antibody fragments have high stability and production yield compared to conventional antibody fragments. This enables new therapeutic applications and reduces production costs. The company has several programs in pre-clinical and clinical development.
ESBATech was acquired by Alcon, Inc., the world’s leading eye care company in 2009 for a cash downpayment of USD 105m (around EUR 72m) followed by further payments to shareholders of up to USD 439m (EUR 299m) based on achievement of future R&D goals.